Figure 1From: Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosisSecreted phospholipase A2 (sPLA2) activity and clinical disease in EAE rats treated with sPLA2 inhibitor CHEC-9. Top: Urinary sPLA2 enzymatic activity, normalized to average pre-immunization values, increased steadily to day 8 in both CHEC-9 and vehicle-treated rats. A significant reduction in activity was observed on days 10 and 12 post-immunization in the peptide treated group either by comparing values of peptide and vehicle directly (p = 0.049, 0.026 respectively, Mann Whitney), or by peak to trough comparison between days 8 and 12, where reduction in sPLA2 levels with peptide treatment was significant (p = 10-3). Bottom: Mean clinical scores from day 10 onwards were also significantly lower in the peptide treated rats (see text).Back to article page